Piero Ruscitti

L'aquila, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 299 publications

Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors.

Expanding the therapeutic landscape of still's disease: the emerging role of JAK inhibitors.

Journal: Expert opinion on pharmacotherapy

Published: August 21, 2026

IL-17 at the eye-joint interface in psoriatic disease: mechanisms, clinical correlates, and therapeutic implications.

IL-17 at the eye-joint interface in psoriatic disease: mechanisms, clinical correlates, and therapeutic implications.

Journal: Expert review of clinical immunology

Published: August 10, 2026

Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still's disease: a systematic literature review informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for assessing disease activity.

Clinical, biological, and radiological changes under therapy, and criteria for clinical response and remission in adult-onset Still's disease: a systematic literature review informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for assessing disease activity.

Journal: EULAR rheumatology open

Published: August 01, 2026

Items identified by expert physicians for the development of the criteria for the assessment of disease activity for adult-onset Still's disease: results of a web-based Delphi study informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for the assessment of disease activity in these patients.

Items identified by expert physicians for the development of the criteria for the assessment of disease activity for adult-onset Still's disease: results of a web-based Delphi study informing the development of the European Alliance of Associations for Rheumatology (EULAR) criteria for the assessment of disease activity in these patients.

Journal: EULAR rheumatology open

Published: August 01, 2026

Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.

Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.

Journal: Clinical rheumatology

Published: June 01, 2026

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

Journal: Clinical and experimental immunology

Published: May 12, 2026

Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS Network.

Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS Network.

Journal: Rheumatology (Oxford, England)

Published: April 16, 2026

Real-world therapeutic strategies in active adult-onset Still's disease: clinical insights from the GIRRCS-AOSD study group.

Real-world therapeutic strategies in active adult-onset Still's disease: clinical insights from the GIRRCS-AOSD study group.

Journal: Frontiers in immunology

Published: April 10, 2026

Dry eye disease in axial spondyloarthritis: heterogeneous ocular surface dysfunction involving tear film instability and tear production from the AIDA network registry.

Dry eye disease in axial spondyloarthritis: heterogeneous ocular surface dysfunction involving tear film instability and tear production from the AIDA network registry.

Journal: Frontiers in medicine

Published: April 09, 2026

TOGETHER-PsA and the case for precision phenotyping in psoriatic arthritis: comment on the article by Merola et al.

TOGETHER-PsA and the case for precision phenotyping in psoriatic arthritis: comment on the article by Merola et al.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 03, 2026

Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.

Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.

Journal: Frontiers in pharmacology

Published: April 03, 2026

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Journal: Seminars in arthritis and rheumatism

Published: February 24, 2026

Showing 1-12 of 299

Last Updated: 09/26/2026